Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Enspryng
Pharma
Enspryng falls short of Roche's expectations in myasthenia gravis
Roche’s labeling Enspryng’s data as weak was a relief for other developers of biologics for gMG, such as Johnson & Johnson, UCB and argenx.
Angus Liu
Mar 21, 2024 11:28am
#FierceMadness: ChemoCentryx beats BioMarin by major margin
Apr 6, 2022 3:00am
Roche wins European approval for subcutaneous NMOSD drug
Jun 29, 2021 8:55am
Roche's new approval Enspryng cuts relapse risk in NMOSD
Sep 10, 2020 9:43am
Roche takes on Alexion, Viela Bio with new NMOSD drug Enspryng
Aug 15, 2020 7:48am
